Completed PHASE1 INTERVENTIONAL 1-arm NCT03790839

Drug Interaction Study Between Dorzagliatin and Sitagliptin

A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Dorzagliatin and Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Sponsor: Hua Medicine Limited

Conditions Patients

Interventions Dorzagliatin Sitagliptin

Updated 6 times since 2019 Last updated: Feb 23, 2023 Started: Jan 31, 2019 Primary completion: Aug 30, 2019 Completion: Aug 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Patients and is currently completed. Hua Medicine Limited leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2023 [monthly]

Completed PHASE1
Oct 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed

▶ Show 1 earlier version

Feb 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hua Medicine Limited

Data source: Hua Medicine Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hackensack, United States